StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma r&d expenses

Research and development expenses are spending on new products and technology.

Matinas BioPharma's R&D Expenses for the twelve months ending Dec 31, 2025 was $85.00K, down 99.3% year over year. For fiscal 2025 it was $85.00K, down 99.3% from the year before. Over ten years it grew -33.8% a year on average. The highest annual figure on record is $16.68M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$85.00K-99.3%
FY2024Dec 31, 2024$11.43M-21.1%
FY2023Dec 31, 2023$14.49M-13.1%
FY2022Dec 31, 2022$16.68M+14.4%
FY2021Dec 31, 2021$14.58M+1.6%
FY2020Dec 31, 2020$14.36M+27.8%
FY2019Dec 31, 2019$11.23M+65.5%
FY2018Dec 31, 2018$6.79M-24.7%
FY2017Dec 31, 2017$9.01M+128.3%
FY2016Dec 31, 2016$3.95M-25.4%
FY2015Dec 31, 2015$5.29M+2.3%
FY2014Dec 31, 2014$5.18M+193.8%
FY2013Dec 31, 2013$1.76M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$85.00K-97.5%
Q4 FY2024Dec 31, 2024$2.38M-35.2%
Q3 FY2024Sep 30, 2024$2.24M-32.0%
Q2 FY2024Jun 30, 2024$3.37M-5.3%
Q1 FY2024Mar 31, 2024$3.45M-13.2%
Q4 FY2023Dec 31, 2023$3.67M-5.2%
Q3 FY2023Sep 30, 2023$3.30M-11.1%
Q2 FY2023Jun 30, 2023$3.56M-13.8%
Q1 FY2023Mar 31, 2023$3.97M-20.2%
Q4 FY2022Dec 31, 2022$3.87M-8.8%
Q3 FY2022Sep 30, 2022$3.71M-19.8%
Q2 FY2022Jun 30, 2022$4.13M+66.4%
Q1 FY2022Mar 31, 2022$4.98M+53.6%
Q4 FY2021Dec 31, 2021$4.24M+20.3%
Q3 FY2021Sep 30, 2021$4.62M+38.5%
Q2 FY2021Jun 30, 2021$2.48M-27.3%
Q1 FY2021Mar 31, 2021$3.24M-20.7%
Q4 FY2020Dec 31, 2020$3.53M+3.1%
Q3 FY2020Sep 30, 2020$3.34M+24.9%
Q2 FY2020Jun 30, 2020$3.41M+20.6%
Q1 FY2020Mar 31, 2020$4.09M+76.6%
Q4 FY2019Dec 31, 2019$3.42M+102.1%
Q3 FY2019Sep 30, 2019$2.67M+93.6%
Q2 FY2019Jun 30, 2019$2.83M+85.8%
Q1 FY2019Mar 31, 2019$2.31M+5.6%
Q4 FY2018Dec 31, 2018$1.69M-26.4%
Q3 FY2018Sep 30, 2018$1.38M-31.5%
Q2 FY2018Jun 30, 2018$1.52M-34.2%
Q1 FY2018Mar 31, 2018$2.19M-8.0%
Q4 FY2017Dec 31, 2017$2.30M+48.5%
Q3 FY2017Sep 30, 2017$2.01M+141.0%
Q2 FY2017Jun 30, 2017$2.31M–
Q1 FY2017Mar 31, 2017$2.38M–
Q4 FY2016Dec 31, 2016$1.55M–
Q3 FY2016Sep 30, 2016$835.31K–

More Matinas BioPharma figures

See a number that looks wrong?